According to the World Health Organization, it is one of the most important tools to overcome the epidemic on a global scale. PrEP (pre-active prophylaxis), available in France since 2016, consists of permanently taking, before taking a risk, double antiretroviral therapy, which subsequently avoids infection in case of contact with HIV. A French-Canadian study (Ipergay) enabled rapid confirmation of its effectiveness, and the evaluation concluded that PrEP was effective “on demand,” that is, before and during certain exposures. Launched in the United States in 2012, it has prevented so many contaminations without ill effects for patients that the approach is now recommended by the WHO.
This approach is even more effective if it can be offered to the majority of people who are exposed to risks they cannot or do not want to avoid. Today, those who have access to it are first of all the people…
Source: Le Figaro
